Allergic conjunctivitis

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Retrieved on: 
Tuesday, November 29, 2022
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Marketing, United, Risk, Therapy, Dry eye syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duane syndrome, Security (finance), RASP, Chronic cough, Patient, Prevalence, Irritation, Pain, Dry, NDA, Allergic conjunctivitis, FDA, COVID-19, Growth, Result, Financial condition report, Lipid peroxidation, Food, Physician, Analysis, Toxicity, Annual report, Inflammation, Disease, Failure, Data analysis, Clinical trial, Safety, PMID, Tears, Conversation, Pharmacology, Biomarker, Asthma, Lubrication, Quality of life, Psoriasis, Alcoholic hepatitis, Eye, Pharmaceutical industry, Schirmer

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease.
  • With data suggesting activity within minutes of administration, reproxalap could provide an important treatment option for the millions of dry eye patients who generally regard currently available therapies as inadequate.
  • Reproxalap is the lead product candidate in Aldeyras RASP modulator platform, which includes systemic disease pipeline candidates ADX-629 and related analogs.
  • In addition to dry eye disease, reproxalap is in late-stage development for allergic conjunctivitis, a condition that is commonly associated with dry eye disease.

Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Investor, Cerebral edema, Private Securities Litigation Reform Act, Retinitis pigmentosa, Review, Allergic conjunctivitis, Marketing, Ocular hypertension, RASP, U.S. Securities and Exchange Commission, Retinal detachment, Conversation, Nasdaq, Uveitis, Research, Risk, Financial condition report, COVID-19, Therapy, Type, SEC, Failure, Annual report, Safety, Securities Exchange Act of 1934, Inflammation, Toxicity, Patient, Pain, Growth, CEO, Analysis, Result, Security (finance), NDA, Duane syndrome, FDA, Pharmaceutical industry, Medical device, Schirmer, Facebook

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2022.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2022.
  • In addition to efficacy data, Aldeyra plans to submit up to 12 months of reproxalap safety data.
  • Pending the results of the pre-NDA meeting, NDA submission may occur as soon as the end of 2022.
  • ET today to discuss recent corporate highlights and financial results for the quarter ended September 30, 2022.

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 8, 2022
Research, Surgery, FDA, Clinical Trials, Other Health, Biotechnology, Health, Optical, Science, Other Science, Investor, NASDAQ, Duane syndrome, Eye, FDA, Allergic conjunctivitis, Ocular hypertension, Retina, Inflammation, Pain, Axitinib, Conference, AMD, Pharmaceutical industry

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:
    Management will be available throughout the day for investor meetings at all three conferences.
  • If you plan to attend at least one of the conferences and are interested in meeting with management, please contact your Jefferies, BTIG or Piper Sandler representative.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.

Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma

Retrieved on: 
Monday, November 7, 2022
Mont Blanc, Kepler, Bimatoprost, Patient, Exercise, Glaucoma, Optical coherence tomography, European Medicines Agency, PGA, Thermes de Saint Gervais Mont-Blanc, Severe cognitive impairment, Drainage, Clinical trial, Partnership, Hemodynamics, IOP, Bausch & Lomb, SGC, COX, Program, Company, LLC, NCX, Mercury (element), Retinal vessel analysis, Fluticasone, NO, Duane syndrome, PGAS, Euronext Paris, Ischemia, Research, AbbVie, EVP, Risk, Human, OCT, Blood, Nitric oxide, Compartment, Eye, Allergic conjunctivitis, Latanoprost, Safety, Internet, Retina, Therapy, Intraocular pressure, Ocular hypertension, NDA, Trabecular meshwork, New Drug Application, Johannes Kepler, Pharmaceutical industry, KREO, NicOx

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • We look forward to continuing the collaboration with Nicox to bring NCX 470 to market, said Liu Ye, Chief Executive Officer of Ocumension Therapeutics.
  • To complement our strong Chinese partnership, and maximize the potential future value of NCX 470, we are actively exploring commercial partnerships for NCX 470 in both the United States and Japanese markets, said Gavin Spencer, EVP, Chief Business Officer of Nicox.
  • NCX 470 is currently in Phase 3 development for the lowering of intraocular pressure in patients with open-angle glaucoma or elevated intraocular pressure.

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

Retrieved on: 
Thursday, November 3, 2022
Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, RASP, Inflammation, Toxicity, Duane syndrome, Retinitis pigmentosa, Allergic conjunctivitis, Patient, Therapy, Nasdaq, Vaccine, Facebook

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m.
  • ET Thursday, November 10, 2022 to report financial results for the quarter ended September 30, 2022 and discuss recent corporate highlights.
  • The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers.
  • A live audio webcast of the conference call also will be accessible from the Investors & Media section of Aldeyras website at https://ir.aldeyra.com/ .

Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22

Retrieved on: 
Wednesday, October 26, 2022
Optical, Science, Health, Research, Diamond, Quality of life, Secrecy, U.S. Securities and Exchange Commission, Water, Retina, Correlation and dependence, ECP, Providence Resources, Versus, Growth, MS, General manager, PST, Tablet, Duration, Contact lens, NYSE, Approximation error, Patient, Lens (anatomy), Duane syndrome, Drink, BSM, Cataract, Eye, Allergic conjunctivitis, Comparison, Private Securities Litigation Reform Act, Doctor of Philosophy, DRS, Industry, CEO, American Academy, File, Allergy, Forward-looking statement, Onset, Academy, Digital, OD, COVID-19, Hilton San Diego Bayfront, Glaucoma, Pharmaceutical industry, Silviculture, Borosilicate glass, Alcon, Astigmatism, Novartis, Aspall Cyder

The meeting coincides with Alcons Diamond Jubilee, celebrating 75 years of helping people see brilliantly.

Key Points: 
  • The meeting coincides with Alcons Diamond Jubilee, celebrating 75 years of helping people see brilliantly.
  • Alcon will host an engaging on-site program featuring events and the latest clinical presentations across contact lenses, allergy, dry eye and more.
  • In 2023, Alcon will expand its MARLO services to provide patients with greater access to eye care.
  • A02491-REP-198231-1 Outermost Surface Softness Analysis of lehfilcon A Contact Lenses and Correlation with Water Content Based upon Petrisoft Gels.

Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting

Retrieved on: 
Wednesday, October 26, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Quality of life, LinkedIn, U.S. Securities and Exchange Commission, Risk, SEC, Therapy, American Academy of Allergy, Asthma, and Immunology, Inflammation, Growth, Annual report, Patient, Result, Twitter, Financial condition report, Security (finance), Allergic conjunctivitis, Nasdaq, Red, Eye, Allergy, Private Securities Litigation Reform Act, Conversation, Marketing, Optometry, Analysis, AAAAI, Toxicity, RASP, Duane syndrome, Securities Exchange Act of 1934, Safety, American Academy, Clinical trial, Failure, COVID-19, Data analysis, Retinitis pigmentosa, Pharmaceutical industry, Vaccine, Facebook

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that an oral presentation highlighting clinical data from the Phase 3 INVIGORATE allergen chamber trial of reproxalap in allergic conjunctivitis will be presented at the American Academy of Optometry 2022 Annual Meeting, taking place in San Diego October 26-29, 2022.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that an oral presentation highlighting clinical data from the Phase 3 INVIGORATE allergen chamber trial of reproxalap in allergic conjunctivitis will be presented at the American Academy of Optometry 2022 Annual Meeting, taking place in San Diego October 26-29, 2022.
  • Reproxalaps mechanism of action has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications.
  • Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species).
  • ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases.

Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results

Retrieved on: 
Monday, October 24, 2022
Biotechnology, FDA, Other Health, Health, General Health, Optical, Other Science, Research, Surgery, Science, Clinical Trials, Retina, Webcast, Eye, NASDAQ, Axitinib, Inflammation, Pain, Duane syndrome, Allergic conjunctivitis, FDA, Ocular hypertension, AMD, Pharmaceutical industry

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2022 financial results after the close on Monday, November 7, 2022.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2022 financial results after the close on Monday, November 7, 2022.
  • Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Companys financial results and provide a general business update.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.

Nicox Provides Third Quarter 2022 Financial and Business Highlights

Retrieved on: 
Wednesday, October 19, 2022
Kepler, Bausch & Lomb, Nitric oxide, Compartment, Therapy, COX, LLC, Johannes Kepler, Patient, Euronext Paris, Research, NCX, NO, Intraocular pressure, IOP, Fluticasone, Vichy, Glaucoma, Latanoprost, Company, Duane syndrome, Allergic conjunctivitis, Safety, Week, COVID-19, Ocular hypertension, Pharmaceutical industry, Mont Blanc

Net revenue 0.8 million for third quarter 2022; cash of 25.6 million on September 30, 2022

Key Points: 
  • Net revenue 0.8 million for third quarter 2022; cash of 25.6 million on September 30, 2022
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial and business highlights for the third quarter 2022 for Nicox SA and its subsidiaries (the Nicox Group) and confirmed timing for the upcoming NCX 470 Mont Blanc Phase 3 clinical trial milestone.
  • Net revenue2 for the third quarter of 2022 was 0.8 million (consisting entirely of net royalty payments).
  • This compares to net revenue for the third quarter of 2021 of 2.4 million (including 0.7 million of net royalty payments and 1.7 million of licensing payments).
  • VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% U.S. prescriptions3 increased by 37% in the third quarter of 2022 compared to the same period in 2021.

Global Allergy Relieving Eye Drops Market Report 2022-2026: Market is Poised to Grow by $354.94 Million - Growing Adoption of Generics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Health, Optical, Adoption, Allergy, CAGR, Plasma protein binding, Mindfulness, Prevalence, Incidence, Allergic conjunctivitis, Eye, Cosmetics, Retail

The "Global Allergy Relieving Eye Drops Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Allergy Relieving Eye Drops Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • This study identifies the growing adoption of generics as one of the prime reasons driving the allergy relieving eye drops market growth during the next few years.
  • The report on the allergy relieving eye drops market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • Also, the allergy relieving eye drops market analysis report includes information on upcoming trends and challenges that will influence market growth.